Patents by Inventor Mark L. Peterson
Mark L. Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210284655Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: ApplicationFiled: February 10, 2021Publication date: September 16, 2021Applicant: CYCLENIUM PHARMA INC.Inventors: Amal WAHHAB, Helmut THOMAS, Luc RICHARD, Mark L. PETERSON, Dwight MACDONALD, Daniel DUBÉ
-
Patent number: 10981931Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: GrantFiled: July 25, 2019Date of Patent: April 20, 2021Assignee: CYCLENIUM PHARMA INC.Inventors: Amal Wahhab, Helmut Thomas, Luc Richard, Mark L. Peterson, Dwight MacDonald, Daniel Dubé
-
Publication number: 20200190083Abstract: The present disclosure relates to novel pyridine-containing macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: ApplicationFiled: June 20, 2018Publication date: June 18, 2020Applicant: CYCLENIUM PHARMA INC.Inventors: Amal WAHHAB, Daniel DUBÉ, Dwight MACDONALD, Mark L. PETERSON, Luc RICHARD, Helmut THOMAS
-
Publication number: 20200157116Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: ApplicationFiled: July 25, 2019Publication date: May 21, 2020Inventors: Amal WAHHAB, Helmut THOMAS, Luc RICHARD, Mark L. PETERSON, Dwight MACDONALD, Daniel DUBÉ
-
Patent number: 10407442Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: GrantFiled: September 14, 2016Date of Patent: September 10, 2019Assignee: CYCLENIUM PHARMA INC.Inventors: Amal Wahhab, Helmut Thomas, Luc Richard, Mark L. Peterson, Dwight Macdonald, Daniel Dubé
-
Publication number: 20190153620Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: ApplicationFiled: May 16, 2017Publication date: May 23, 2019Inventors: Dwight MACDONALD, Daniel DUBÉ, Amal WAHHAB, Helmut THOMAS, Luc RICHARD, Mark L. PETERSON
-
Patent number: 10258602Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: March 28, 2018Date of Patent: April 16, 2019Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Publication number: 20180265521Abstract: The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.Type: ApplicationFiled: September 14, 2016Publication date: September 20, 2018Inventors: Amal WAHHAB, Helmut THOMAS, Luc RICHARD, Mark L. PETERSON, Dwight MACDONALD, Daniel DUBÉ
-
Publication number: 20180228768Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: March 28, 2018Publication date: August 16, 2018Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Patent number: 10040751Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: GrantFiled: October 1, 2015Date of Patent: August 7, 2018Assignee: Ocera Therapeutics, Inc.Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 9949949Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: June 9, 2016Date of Patent: April 24, 2018Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Publication number: 20170042858Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: June 9, 2016Publication date: February 16, 2017Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Publication number: 20160221927Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: ApplicationFiled: October 1, 2015Publication date: August 4, 2016Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Oullet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 9371297Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: February 8, 2008Date of Patent: June 21, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
-
Patent number: 8557765Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: May 26, 2009Date of Patent: October 15, 2013Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
-
Patent number: 8497242Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: GrantFiled: February 28, 2011Date of Patent: July 30, 2013Assignee: Tranzyme Pharma Inc.Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 8450268Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: December 11, 2008Date of Patent: May 28, 2013Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Patent number: 8440851Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: February 28, 2011Date of Patent: May 14, 2013Assignee: Tranzyme Pharma, Inc.Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 8349887Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: June 30, 2011Date of Patent: January 8, 2013Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Publication number: 20120071412Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.Type: ApplicationFiled: November 28, 2011Publication date: March 22, 2012Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson